‫ستاندرد تشارترد يطلق الحساب الإسلامي المستدام في الإمارات العربية المتحدة

الوطنية لصناعة معدات مكافحة الحرائق (نافكو) هي أول شركة تستخدم الحساب الإسلامي المستدام في دولة الإمارات العربية المتحدة

Standard Chartered launches Islamic Sustainable Account in the UAEدبي، الإمارات العربية المتحدة29 نوفمبر / تشرين ثاني 2022 /PRNewswire/ — أعلن بنك ستاندرد تشارترد اليوم عن إطلاق الحساب الإسلامي المستدام في دولة الإمارات العربية المتحدة، وهو منتج فريد من نوعه يقدم للشركات الكبيرة من عملاء البنك فرصة لدمج الاستدامة في إدارتهم النقدية مع الحفاظ خيار الوصول اليومي إلى أموالهم لتلبية احتياجات إدارة السيولة.

وسيتم استخدام الودائع في الحسابات الإسلامية المستدامة المتوافقة مع الشريعة الإسلامية لتمويل المشاريع المستدامة بناءً على إطار عمل المنتجات الخضراء والمستدامة من بنك ستاندرد تشارترد، والذي يتماشى مع أهداف الأمم المتحدة للتنمية المستدامة.

وفي معرض تعليقها على إطلاق هذا المنتج، قالت رولا أبو منه، الرئيس التنفيذي لبنك ستاندرد تشارترد في دولة الإمارات العربية المتحدة: “في ظل ارتفاع وتيرة التنمية المستدامة في جميع أنحاء دولة الإمارات العربية المتحدة، تعمل الشركات جاهدة على ايجاد طرق مختلفة تتماشى مع انظمتهم للمشاركة في تطبيقها. لذلك، قام بنك ستاندرد تشارترد بإضافة حلول مبتكرة عن طريق الحساب الإسلامي المستدام الذي يوفر للعملاء فرصة ترسيخ فائض أرصدتهم النقدية للمشاركة في التمويل المستدام والمشاريع التي يمولها البنك مثل مشاريع الطاقة الشمسية ومرافق المياه وغيرها.”

وأضافت: “نافكو، التي التزمت بتخفيض انبعاثات ثاني أكسيد الكربون الناتجة عن عملياتها من خلال تنفيذ برامج إدارة خفض استهلاك الموارد الطبيعية، هي أول مؤسسة في دولة الإمارات تستخدم بشكل استباقي الحساب الإسلامي المستدام لدعم فرص النمو المستدام والشامل.”

والجدير بالذكر أن صياغة إطار عمل المنتجات الخضراء والمستدامة من بنك ستاندرد تشارترد تمت بالتعاون مع خبراء الصناعة Sustainalytics  

نبذة عن بنك ستاندرد تشارترد :

بنك ستاندرد تشارترد هو مجموعةً مصرفيةً عالميةً رائدةً، يتواجد في 59 سوقاً من أكثر أسواق العالم حيوية، ونقدم الخدمات لعملائنا في 85 دولة أخرى. ويتمثل هدفنا في تعزيز التجارة والازدهار في العالم من خلال التنوع الفريد الذي نوفره. ويتبنّى البنك رؤيةً واضحةً تحت شعار “هنا دائماً للأفضل” والتي تعكس التراث العريق والقيم المؤسسية التي ينتهجها البنك في أعماله .

ولا بدّ من التنويه أن “ستاندرد تشارترد” مدرج في الأسواق المالية في كل من لندن وهونج كونج .

للاطلاع على مزيد من المعلومات وآراء الخبراء، يرجى زيارة قسم Insights  على موقعنا الإلكتروني sc.com . كما يمكنكم متابعتنا على مواقع التواصل الاجتماعي: لينكد إن و تويتر و فيسبوك .

لصورة – https://mma.prnewswire.com/media/1957776/Rola_Abu_Manneh_CEO.jpg

‫تركيبة وصوت غنيين – تلفزيون M550L من Toshiba

هونغ كونغ، 29 نونبر/تشرين الثاني 2022 / PRNewswire / — تم الإعلان عن تلفزيون Toshiba TV باعتباره التلفزيون الرسمي لكأس العالم FIFA قطر 2022. حظي تلفزيون M550L من Toshiba منذ إطلاقه في الأسواق المحلية في جميع أنحاء العالم، بالاستحسان على شاشة العرض والصوت وأداء النظام، مما يجعله خيارًا رقميًا مناسبًا للترفيه المنزلي عالي الجودة.

تماشيًا مع التزام Toshiba TV بالتكنولوجيا المبتكرة، فإن تلفزيون M550L يأتي بعدد من الميزات المميزة للحصول على أفضل قيمة يمكن تحقيقها في نطاق التكلفة. تم تضمين ميزة استعادة الملمس الرائعة في واجهة العرض الخاصة بها، والتي تسمح لتلفزيون M550L من Toshiba بتحسين الصور وترقيتها إلى أفضل تركيب للحصول على وضوح صورة يقارب 4K . تعمل استعادة الصور أثناء المشاهدة على الحفاظ على الدقة المثلى لمتعة المشاهد.

تلفزيون M550L من Toshiba هو أيضًا مصدر طاقة صوتي، ومجهز بـ REGZA Power Audio PRO و Dolby Atmos المكرر صوتيًا. تتحد هذه الميزات لإنتاج صوت جهير مثير ودرجات صوت مضبوطة بدقة وطبيعية، والتي يشتهر بها تلفزيون M550L دون أي تناقضات. تخطو صوتيات Dolby Atmos خطوة إلى الأمام في إعادة تعريف المشهد الصوتي الذي ينشئه تلفزيون M550L من Toshiba ، وترتقي بتجربة السينما المنزلية إلى ارتفاعات غامرة أعلى مع نظام الصوت المحيطي.

يشير نظام الصوت المحيطي المتوهج الخاص بجهاز M550L تلفزيون Toshiba إلى النقل الخالي من العيوب للأصوات من خلال قنوات الإخراج المتعددة التي تحيط بالمشاهد وتملأ الغرفة بأعلى الأصوات من المحتويات التي يشاهدها. سواء كان ذلك للألعاب أو الأفلام، فقد تم تصميم نظام M550L المحيطي لتقديم أصوات بدقة فاخرة وأعماق ساحرة لإكمال تجربة المشاهدة التي لا تُنسى.

لمعرفة المزيد، تابع أخبار Toshiba TV على فايسبوك و إنستغرام و تويتر و يوتيوب .

الصورة – https://mma.prnewswire.com/media/1955416/image_5022994_28247910.jpg

Challenge new enemies in MIR4! New raid and boss raid revealed!

  • Vipergeist Prison and Claydoh GEN now available, big rewards for the first kill
  • Antidemon Chamber, Magic Square that gives high EXP, unlocked
  • New monthly check-in event “Lucky Cat Luckster’s Monthly Check-in” updated

SEOUL, South Korea, Nov. 29, 2022 /PRNewswire/ — Wemade’s blockbuster MMORPG MIR4 revealed a new raid and boss raid on Nov 29.

New Boss Raid 'Claydoh GEN' Update

In Vipergeist Prison, the new 14th stage of the raid, Lv. 165 monsters appear whereas in Claydoh GEN, the 10th stage of boss raid, a Lv. 160 boss monster appears.

In Claydoh GEN, the boss attacks frequently by swinging a long sword, summoning Claydoh Witch Doctor and forming a dust storm all at once. To fight back, users need to fight together and have high HP.

Through this update, users can experience more challenging raid and boss raid contents. Epic Blue Dragon Statue, Rare Divine Dragon’s Enhancement Stone, Legendary Mystic Enhancement Stone, and other rewards are given upon defeating the raid for the first time.

Antidemon Chamber is available on the 6-8th floor of Magic Square. When players attack monsters in the chamber, they can deal more damage with their Antidemon Power and acquire greater EXP through battles.

New monthly check-in event “Lucky Cat Luckster’s Monthly Check-in” has also been updated. This event runs until December 27th and users can receive various items such as Vigor Pills for rapid growth, Dragon Sphere Summon Tickets and Hell Raid Tickets.

From my battle, to our war! Check out the official website for more info on MIR4.

Photo – https://mma.prnewswire.com/media/1957133/image1.jpg

Logo – https://mma.prnewswire.com/media/1848100/MIR4_Logo.jpg

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

GAITHERSBURG, Md., Nov. 29, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.

“Today’s updated Emergency Use Listing from the WHO allows us to offer our protein-based vaccine as a primary series to adolescents and as a booster for adults around the world,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “WHO member countries now have a vaccine option for these indications developed using an innovative approach to traditional technology that can also be stored in standard refrigeration, making it easy to transport.”

Novavax LogoPrimary Series in Adolescents
The updated EUL for Nuvaxovid as a primary series in adolescents aged 12 through 17 was based on data from the ongoing pediatric expansion of the Phase 3 PREVENT-19 trial of 2,232 adolescents aged 12 through 17 years across 75 sites in the U.S., to evaluate the safety and effectiveness of Nuvaxovid. In the pediatric expansion, Nuvaxovid achieved its primary effectiveness endpoint and demonstrated 80% clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S.

Preliminary safety data from the pediatric expansion showed the vaccine to be generally well-tolerated. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, and not considered related to the vaccine. Local and systemic reactogenicity was generally lower than or similar to adults, after the first and second dose. The most common adverse reactions observed were injection site tenderness/pain, headache, myalgia, fatigue, and malaise. There was no increase in reactogenicity in younger (12 to <15 years old) adolescents compared to older (15 to <18 years old) adolescents. No new safety signal was observed through the placebo-controlled portion of the pediatric expansion.

Booster in Adults
The updated EUL for Nuvaxovid as a booster in adults aged 18 and older is supported by data from Novavax’ Phase 2 trial conducted in Australia, from a separate Phase 2 trial conducted in South Africa, and from the United Kingdom (U.K.)-sponsored COV-BOOST trial. As part of the Novavax Phase 2 trials, a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after their primary two-dose vaccination series of Nuvaxovid. The third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials. In the COV-BOOST trial, Nuvaxovid induced a meaningful antibody response when used as a heterologous third booster dose.

In the Novavax-sponsored trials, following the booster, local and systemic reactions had a median duration of approximately two days. The incidence of Grade 3 or higher events remained relatively low. Safety reporting of reactogenicity events showed an increasing incidence across all three doses of Nuvaxovid, often seen with increased immunogenicity. Medically attended adverse events (AE), potentially immune-mediated medical conditions, and severe AEs occurred infrequently following the booster dose and were balanced between vaccine and placebo groups.

In the 12 through 17-year-old population, Novavax’ vaccine has been authorized in more than 10 markets including the U.S., the European Union (EU), and the U.K. The vaccine has also been authorized as a booster in the U.S.EUJapanAustraliaNew Zealand, and Switzerland, and a number of other countries have policy recommendations allowing use of the vaccine as a heterologous or homologous booster dose. Novavax’ vaccine is actively under review in other markets for both indications and has ongoing trials to further explore its efficacy and safety as a booster.

The WHO previously granted EUL for Nuvaxovid in adults aged 18 and older in December 2021.

Trade Name in the U.S.
The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration (FDA).

Important Safety Information: WHO

  • Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
  • Events of anaphylaxis have been reported with administration of Nuvaxovid. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at least 15 minutes is recommended and a second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid.
  • Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
  • Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination.
  • Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
  • The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
  • Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
  • The effects with Nuvaxovid may temporarily affect the ability to drive or use machines.
  • Individuals may not be fully protected until 7 days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients.
  • The most frequent adverse reactions in clinical trials in individuals 12 years of age and older were headache, nausea or vomiting myalgia, arthralgia, injection site tenderness, injection site pain, fatigue, and malaise.

For more information on Nuvaxovid, including the Summary of Product Characteristics with Package Leaflet, adverse event reporting instructions, or to request additional information, please visit the following websites:

About Nuvaxovid™ (NVX-CoV2373)
Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Nuvaxovid contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.

Novavax has established partnerships for the manufacture, commercialization, and distribution of Nuvaxovid worldwide. Existing authorizations leverage Novavax’ manufacturing partnership with Serum Institute of India, the world’s largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax’ global supply chain.

About the Novavax COVID-19 vaccine (NVX-CoV2373) Phase 3 Trials
The Novavax COVID-19 vaccine (NVX-CoV2373) continues being evaluated in two pivotal Phase 3 trials.

PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of the Novavax COVID-19 vaccine with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations in the U.S. and Mexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, the Novavax COVID-19 vaccine achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in the New England Journal of Medicine (NEJM).

The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of the Novavax COVID-19 vaccine with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the U.S., compared with placebo. In the pediatric trial, the vaccine achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S. Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.

Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published in NEJM.

About Matrix-M™ Adjuvant
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including the U.S. FDA, the European Commission, and the WHO. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its COVID-19-Influenza Combination (CIC) vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on LinkedIn.

Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, NVX-CoV2515 and a bivalent Omicron-based / original strain based vaccine, the CIC investigational vaccine candidate, a quadrivalent influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax’ plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax’ global supply chain, additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents, and as a booster, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, the efficacy, safety, intended utilization, and expected administration of NVX-CoV2373, and the expected administration of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; unanticipated challenges or delays in conducting clinical trials; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Novavax’ Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com

Media
Ali Chartan or Giovanna Chandler | 202-709-5563
media@novavax.com

Logo – https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg

‫ماج تكشف عن كيتورا ريزيرف في ميدان، دبي بقيمة 3 مليارات درهم

·  المشروع ينطلق من مفهوم “العيش البيولوجي” المندمج مع الطبيعة ليكون الأول من نوعه في الشرق الأوسط

دبى، الامارات العربية المتحدة, 29 نوفمبر / تشرين ثاني 2022 /PRNewswire/ — أعلنت ماج، المطور العقاري الرائد في الإمارات، عن إطلاق كيتوراريزيرف، المشروع السكني الفاخر الجديد بمواصفاته الحصرية والمبتكرة بقيمة 3 مليارات درهم في ميدان، إحدى أكثر المناطق السكنية جاذبية في دبي. ويقدم المشروع نموذجاً تحويلياً في حياة قاطنيه، وذلك من خلال التصميم الاستثنائي للمساحات، ليكون بذلك أول مشروع سكني في الشرق الأوسط يتيح لسكانه الاندماج التام مع الطبيعة. ولتحقيق هذه الغاية، عمدت الشركة إلى تطبيق مفهوم “العيش البيولوجي” الذي يدمج الطبيعة في البيئة المبنية، الأمر الذي يسهم في تحسين الصحة الجسدية والعقلية والعاطفية لسكانه. ومن المقرر الانتهاء من تطويره في الربع الربع الثاني2025.

Keturah Reserve

وتضم كيتورا ريزيرف منازل فخمة مؤلفة من فلل وشقق تضم غرفة وغرفتين وثلاث غرف وأربع غرف. وسيكون المشروع معززاً بالعديد من المرافق، بما في ذلك المساحات المجتمعية الواسعة وحمام السباحة الخارجي، والصالات الرياضية للنساء والرجال، إضافة إلى السبا، مع وجود المطاعم، ومرافق الرعاية الصحية.

وهناك مجموعة من الأنشطة الأخرى التي يوفرها المشروع، ومنها استوديو بيلاتيس ومسبح الدراجات المائية، وتقديم دروس التمارين الهوائية وجلسات التأمل على السطح ومساحات مخصصة لممارسة اليوغا.

وتركز كيتورا ريزيرف على تعزيز الذات الداخلية، لأنها مستوحاة من مفهوم “التوافق من الداخل إلى الخارج”، مع الأخذ هذا البعد في الحسبان عند تطوير جميع المرافق والأنشطة وخدمات الطعام والشراب.

وتوجد حديقة في قلب المشروع، وستكون عبارة عن مساحة خضراء تنتشر في أرجائها المناظر طبيعية الخلابة فوق مساحة قدرها 300,000 قدم مربع، حيث يمكن للسكان الاستفادة منها لتجديد الطاقة. وستظللها أشجار زيتون يتجاوز عمر الواحدة منها ألف عام، وتم الحصول عليها من وجهات عالمية، للتذكير بأصول عائلة القداح كمزارعين ومالكين لمزارع الزيتون.

وتتميز المنازل في كيتورا ريزيرف بمواقعها المحددة بزاويا معينة لالتقاط ضوء النهار الطبيعي وتوظيفه للإنارة الداخلية وبطريقة لا تؤدي إلى زيادة الحرارة أو الوهج. وتعمل المساحات الداخلية الفسيحة على زيادة تدفق الهواء المبرد بشكل طبيعي، ما يقلل الحاجة إلى تكييف الهواء. ومن جهة أخرى، صممت المساحات المفتوحة أيضاً بدون ممرات، مع استخدام أثاث وتجهيزات مصممة خصيصاً على نحو يناسب كل مساحة لتحسين حرية الحركة.

وصممت كيتورا التي تعد جزءاً من العلامة التجارية الجديدة للضيافة والعقارات الفاخرة “كيتورا”، من قبل المهندس المعماري الشهير تشارلي وو.

وفي تعليقه على هذا المشروع، قال طلال موفق القداح، الرئيس التنفيذي لمجموعة ماج: “ يحمل هذا المشروع تصميماً فريداً مع الاهتمام بكافة التفاصيل بدقة لإثراء حياة سكانها. إننا نرى في هذا المشروع خياراً مثالياً للعيش الفاخر مع الإحساس الحقيقي بالحياة المجتمعية.”

https://mma.prnewswire.com/media/1957610/Keturah_Reserve.jpg

The report on the state of the world’s water resources provides data on rivers, terrestrial water storage and glaciers

The World Meteorological Organization (WMO) has published the first report on the state of the world’s water resources , assessing the effects of climate, environmental and social change on the Earth’s water resources. . The objective of this annual balance sheet is to support the monitoring and management of the world’s freshwater resources at a time characterized by increasing demand and limited supply.

The report provides a summary of the river flow, as well as the main floods and droughts. Perspectives are offered on hotspots in terms of changes in freshwater storage, while highlighting the essential role and vulnerability of the cryosphere (snow and ice).

The report notes that drier-than-normal conditions were recorded across large areas of the planet in 2021, a year in which rainfall distribution was influenced by climate change and a La Niña episode. The area with below-mean stream flow was approximately twice as large as the area above the mean, compared to the 30-year hydrologic mean.

“The impacts of climate change tend to manifest themselves through water, with more intense and frequent droughts, more extreme floods, more irregular seasonal rains and the acceleration of the melting of glaciers, and generate cascading effects on economies, ecosystems and all aspects of our daily lives. However, insufficient knowledge is available on changes in the distribution, quantity and quality of freshwater resources,” said WMO Secretary-General Professor Petteri Taalas.

“The State of the World’s Water Resources report aims to fill this knowledge gap and provide a concise overview of water availability in different parts of the world. These data will guide investments in climate-linked mitigation and adaptation activities, as well as the United Nations campaign to focus on providing universal access within the next five years to early warnings of hazards such as floods and droughts.” added Professor Taalas.

Currently, 3.6 billion people have inadequate access to water for at least one month of the year, and this number is projected to increase to more than 5 billion by 2050. Between 2001 and 2018, UN-Water gave to know that 74% of all natural disasters were related to water. At the recent United Nations climate change conference (27th Conference of the Parties to the United Nations Framework Convention on Climate Change), governments were urged to further integrate water into adaptation initiatives, which It marks the first time that water has been referred to in an outcome document of a Conference of the Parties in recognition of its critical importance.

In the first edition of the report, river flow is examined, that is, the volume of water that flows through a river channel at a given time. Likewise, terrestrial water storage is evaluated, that is, all the water found on the terrestrial surface and subsurface and the cryosphere (frozen water).

The information and supplementary maps are based primarily on modeled data (for maximum geographic coverage) as well as remotely sensed information from the Gravity Recovery Experiment and Climate (GRACE) land-based water storage mission. National Aeronautics and Space Administration (NASA). Model results were validated against observed data, where available.

In the report, the lack of verified and accessible hydrological data is emphasized. The WMO Unified Data Policy seeks to accelerate the availability and sharing of hydrological data, including information on river flows and transboundary river basins.

River flow

Drier-than-normal conditions were recorded in 2021 over large areas of the globe, compared to the average 30-year reference hydrological period.

Among them, it is worth mentioning the Río de la Plata area in South America, where a persistent drought has affected the region since 2019, the south and southeast of the Amazon, and some basins in North America, for example, the of the Colorado, Missouri, and Mississippi rivers.

In Africa, some rivers, including the Niger, Volta, Nile, and Congo, had lower-than-normal flows in 2021. Also, some rivers in parts of Russia, western Siberia, and Central Asia had below-average flows. in 2021.

Higher-than-normal river flows were observed in some basins in North America, northern Amazonia, and southern Africa (Zambezi and Orange), as well as in China (the Amur River basin) and northern India.

Approximately one third of the areas analyzed corresponded to the 30-year average.

Major floods with many casualties have been reported, for example, in China (Henan Province), northern India, western Europe and tropical cyclone-affected countries such as Mozambique, the Philippines and Indonesia.

Ethiopia, Kenya and Somalia have faced several consecutive years of below-average rainfall that have caused a regional drought.

Source: World Meteorological Organization